|
|
 Previous Article | Table of Contents | Next Article 
N-ras mutations in adult de novo acute myelogenous leukemia: prevalence and
clinical significance
JP Radich, KJ Kopecky, CL Willman, J Weick, D Head, F Appelbaum and SJ Collins
Molecular Medicine Program, Fred Hutchinson Cancer Research Center,
Seattle, WA 98104.
Point mutations of the N-ras proto-oncogenes have been previously detected
in 20% to 60% of samples of acute myelogenous leukemia (AML), but the
clinical significance of these mutations is presently unclear. We directly
sequenced polymerase chain reaction (PCR) amplified N-ras fragments to
determine the frequency of N-ras point mutations in 55 adult patients with
de novo AML. Mutations were present in 8 of 55 (15%) patients. These
mutations were usually in codon 12, 13, or 61, but one patient had
mutations in both codons 13 and 61, and another had an unusual point
mutation in N-ras codon 60. A comparison of patients with and without N-ras
mutations showed no statistically significant differences in pretreatment
clinical variables, response to induction therapy, or survival, except for
a possibly higher percentage of FAB M4 subtypes in patients with the N-ras
mutation. These data together with previous reports suggest that the
presence of N-ras point mutations do not clearly define a unique clinical
or biologic subset of AML patients.
Volume 76,
Issue 4,
pp. 801-807,
08/15/1990
Copyright © 1990 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
A. Neubauer, K. Maharry, K. Mrozek, C. Thiede, G. Marcucci, P. Paschka, R. J. Mayer, R. A. Larson, E. T. Liu, and C. D. Bloomfield
Patients With Acute Myeloid Leukemia and RAS Mutations Benefit Most From Postremission High-Dose Cytarabine: A Cancer and Leukemia Group B Study
J. Clin. Oncol.,
October 1, 2008;
26(28):
4603 - 4609.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. P. Radich
Molecular Classification of Acute Myeloid Leukemia: Are We There Yet?
J. Clin. Oncol.,
October 1, 2008;
26(28):
4539 - 4541.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Si and S. J. Collins
Activated Ca2+/Calmodulin-Dependent Protein Kinase II{gamma} Is a Critical Regulator of Myeloid Leukemia Cell Proliferation
Cancer Res.,
May 15, 2008;
68(10):
3733 - 3742.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
U. Bacher, T. Haferlach, W. Kern, C. Haferlach, and S. Schnittger
A comparative study of molecular mutations in 381 patients with myelodysplastic syndrome and in 4130 patients with acute myeloid leukemia
Haematologica,
June 1, 2007;
92(6):
744 - 752.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. L. Brown, C. R. Wilkinson, S. R. Waterman, C. H. Kok, D. G. Salerno, S. M. Diakiw, B. Reynolds, H. S. Scott, A. Tsykin, G. F. Glonek, et al.
Genetic regulators of myelopoiesis and leukemic signaling identified by gene profiling and linear modeling
J. Leukoc. Biol.,
August 1, 2006;
80(2):
433 - 447.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
U. Bacher, T. Haferlach, C. Schoch, W. Kern, and S. Schnittger
Implications of NRAS mutations in AML: a study of 2502 patients
Blood,
May 15, 2006;
107(10):
3847 - 3853.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. F. Goemans, C. M. Zwaan, A. Harlow, A. H. Loonen, B. E. S. Gibson, K. Hahlen, D. Reinhardt, U. Creutzig, M. C. Heinrich, and G. J. L. Kaspers
In vitro profiling of the sensitivity of pediatric leukemia cells to tipifarnib: identification of T-cell ALL and FAB M5 AML as the most sensitive subsets
Blood,
November 15, 2005;
106(10):
3532 - 3537.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Suzuki, H. Kiyoi, K. Ozeki, A. Tomita, S. Yamaji, R. Suzuki, Y. Kodera, S. Miyawaki, N. Asou, K. Kuriyama, et al.
Clinical characteristics and prognostic implications of NPM1 mutations in acute myeloid leukemia
Blood,
October 15, 2005;
106(8):
2854 - 2861.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. T. Bowen, M. E. Frew, R. Hills, R. E. Gale, K. Wheatley, M. J. Groves, S. E. Langabeer, P. D. Kottaridis, A. V. Moorman, A. K. Burnett, et al.
RAS mutation in acute myeloid leukemia is associated with distinct cytogenetic subgroups but does not influence outcome in patients younger than 60 years
Blood,
September 15, 2005;
106(6):
2113 - 2119.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Frohling, C. Scholl, D. G. Gilliland, and R. L. Levine
Genetics of Myeloid Malignancies: Pathogenetic and Clinical Implications
J. Clin. Oncol.,
September 10, 2005;
23(26):
6285 - 6295.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Kamata, J. Kang, T.-H. Lee, L. Wojnowski, C. A. Pritchard, and A. D. Leavitt
A critical function for B-Raf at multiple stages of myelopoiesis
Blood,
August 1, 2005;
106(3):
833 - 840.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. M. Wiesner, J. M. Jones, D. E. Hasz, and D. A. Largaespada
Repressible transgenic model of NRAS oncogene-driven mast cell disease in the mouse
Blood,
August 1, 2005;
106(3):
1054 - 1062.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Recher, O. Beyne-Rauzy, C. Demur, G. Chicanne, C. Dos Santos, V. M.-D. Mas, D. Benzaquen, G. Laurent, F. Huguet, and B. Payrastre
Antileukemic activity of rapamycin in acute myeloid leukemia
Blood,
March 15, 2005;
105(6):
2527 - 2534.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. E. Ross, R. Mahfouz, M. Onciu, H.-C. Liu, X. Zhou, G. Song, S. A. Shurtleff, S. Pounds, C. Cheng, J. Ma, et al.
Gene expression profiling of pediatric acute myelogenous leukemia
Blood,
December 1, 2004;
104(12):
3679 - 3687.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Dorrell, K. Takenaka, M. D. Minden, R. G. Hawley, and J. E. Dick
Hematopoietic Cell Fate and the Initiation of Leukemic Properties in Primitive Primary Human Cells Are Influenced by Ras Activity and Farnesyltransferase Inhibition
Mol. Cell. Biol.,
August 15, 2004;
24(16):
6993 - 7002.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Barletta, G. Gorini, P. Vineis, L. Miligi, L. Davico, G. Mugnai, S. Ciolli, F. Leoni, M. Bertini, G. Matullo, et al.
Ras gene mutations in patients with acute myeloid leukaemia and exposure to chemical agents
Carcinogenesis,
May 1, 2004;
25(5):
749 - 755.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Ozeki, H. Kiyoi, Y. Hirose, M. Iwai, M. Ninomiya, Y. Kodera, S. Miyawaki, K. Kuriyama, C. Shimazaki, H. Akiyama, et al.
Biologic and clinical significance of the FLT3 transcript level in acute myeloid leukemia
Blood,
March 1, 2004;
103(5):
1901 - 1908.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L.-Y. Shih, C.-F. Huang, J.-H. Wu, P.-N. Wang, T.-L. Lin, P. Dunn, M.-C. Chou, M.-C. Kuo, and C.-C. Tang
Heterogeneous Patterns of FLT3 Asp835 Mutations in Relapsed de Novo Acute Myeloid Leukemia: A Comparative Analysis of 120 Paired Diagnostic and Relapse Bone Marrow Samples
Clin. Cancer Res.,
February 15, 2004;
10(4):
1326 - 1332.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. E. Lancet and J. E. Karp
Farnesyltransferase inhibitors in hematologic malignancies: new horizons in therapy
Blood,
December 1, 2003;
102(12):
3880 - 3889.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. S. Clark, L. Zhong, D. Filiault, S. Perman, Z. Ren, M. Gould, and X. Yang
Anti-Leukemia Effect of Perillyl Alcohol in Bcr/Abl-Transformed Cells Indirectly Inhibits Signaling through Mek in a Ras- and Raf-Independent Fashion
Clin. Cancer Res.,
October 1, 2003;
9(12):
4494 - 4504.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Meshinchi, D. L. Stirewalt, T. A. Alonzo, Q. Zhang, D. A. Sweetser, W. G. Woods, I. D. Bernstein, R. J. Arceci, and J. P. Radich
Activating mutations of RTK/ras signal transduction pathway in pediatric acute myeloid leukemia
Blood,
August 15, 2003;
102(4):
1474 - 1479.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R.K. WILSON, T.J. LEY, F.S. COLE, J.D. MILBRANDT, S. CLIFTON, L. FULTON, G. FEWELL, P. MINX, H. SUN, M. MCLELLAN, et al.
Mutational Profiling in the Human Genome
Cold Spring Harb Symp Quant Biol,
January 1, 2003;
68(0):
23 - 30.
[Abstract]
[PDF]
|
|
|
|
|
|
|
L.-Y. Shih, C.-F. Huang, J.-H. Wu, T.-L. Lin, P. Dunn, P.-N. Wang, M.-C. Kuo, C.-L. Lai, and H.-C. Hsu
Internal tandem duplication of FLT3 in relapsed acute myeloid leukemia: a comparative analysis of bone marrow samples from 108 adult patients at diagnosis and relapse
Blood,
September 18, 2002;
100(7):
2387 - 2392.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. L. Stirewalt, K. J. Kopecky, S. Meshinchi, F. R. Appelbaum, M. L. Slovak, C. L. Willman, and J. P. Radich
FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia
Blood,
June 1, 2001;
97(11):
3589 - 3595.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Yamamoto, H. Kiyoi, Y. Nakano, R. Suzuki, Y. Kodera, S. Miyawaki, N. Asou, K. Kuriyama, F. Yagasaki, C. Shimazaki, et al.
Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies
Blood,
April 15, 2001;
97(8):
2434 - 2439.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. R. Appelbaum, J. M. Rowe, J. Radich, and J. E. Dick
Acute Myeloid Leukemia
Hematology,
January 1, 2001;
2001(1):
62 - 86.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. Bodo, M. Peters, J. P. Radich, J. Hess, M. Blinder, M. S. Watson, R. Van Rheeden, S. Natarajan, J. A. Lowell, R. Brown, et al.
Donor-Derived Acute Promyelocytic Leukemia in a Liver-Transplant Recipient
N. Engl. J. Med.,
September 9, 1999;
341(11):
807 - 813.
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Kiyoi, T. Naoe, Y. Nakano, S. Yokota, S. Minami, S. Miyawaki, N. Asou, K. Kuriyama, I. Jinnai, C. Shimazaki, et al.
Prognostic Implication of FLT3 and N-RAS Gene Mutations in Acute Myeloid Leukemia
Blood,
May 1, 1999;
93(9):
3074 - 3080.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Dimitroulakos, D. Nohynek, K. L. Backway, D. W. Hedley, H. Yeger, M. H. Freedman, M. D. Minden, and L. Z. Penn
Increased Sensitivity of Acute Myeloid Leukemias to Lovastatin-Induced Apoptosis: A Potential Therapeutic Approach
Blood,
February 15, 1999;
93(4):
1308 - 1318.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D J Phillips, J M Benson, J M Pruckler, and W C Hooper
PCR regimen for enhanced specificity and yield of targeted genomic DNA sequences: ras and p53.
Genome Res.,
August 1, 1992;
2(1):
45 - 50.
[Abstract]
[PDF]
|
|
|
|
|
